The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFusion Antibody Regulatory News (FAB)

Share Price Information for Fusion Antibody (FAB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.40
Bid: 3.30
Ask: 3.50
Change: 0.00 (0.00%)
Spread: 0.20 (6.061%)
Open: 3.40
High: 3.40
Low: 3.40
Prev. Close: 3.40
FAB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Executive Officer

28 Jul 2022 07:00

RNS Number : 9768T
Fusion Antibodies PLC
28 July 2022
 

Fusion Antibodies plc

("Fusion" or the "Company")

 

Appointment of Chief Executive Officer

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the appointment of Dr Adrian Kinkaid as Chief Executive Officer ("CEO"), effective from Monday 15 August 2022. Adrian's appointment follows an extensive formal search process further to the Company's announcement on 14 March 2022.

 

Adrian Kinkaid is an experienced life sciences executive with 25 years' experience in life science and biotherapeutics industries. He joins Fusion from Vortex Liquid Biopsy Solutions Ltd and Vortex Biosciences Inc. (together "Vortex"), a biotech group focused on world class technology for the isolation of high quality circulating tumour cells. As CEO of Vortex, Adrian led the company's development, including management of its business units.

 

Prior to joining Vortex, Adrian worked as CEO at several antibody-based diagnostics companies including BioFab Ltd, and Lumabs BV. He was formerly the Chief Commercial Officer for Promexus Ltd, a protein biotherapeutics company where he developed the corporate strategy for Therapeutic Affimers, culminating in a multi-target deal with a potential of over $1bn.  Adrian was previously Chief Business Officer of the Aptamer Group, and Strategic Market Development Leader for Abcam plc, the leading provider of research antibodies. 

 

Adrian has a PhD in Biochemistry and undertook postdoctoral research with the Institute of Cancer Research, London. As Chairman and founding member of the European Laboratory Research and Innovation Group, Adrian established their flagship Drug Discovery event, which is now the leading conference of its kind in Europe.

 

Simon Douglas, Chairman of Fusion Antibodies, commented: "I would like to welcome Adrian who joins Fusion at an exciting time as we focus on growing our antibody services and completing the development of and commercial roll out next year of OptiMAL, our Mammalian Antibody library."

 

Adrian Kinkaid said: "I am delighted to be joining Fusion Antibodies at this exciting time of growth and look forward to leading the Company to further commercial success. Fusion Antibodies has a world class technology platform built over the last decade that has the potential to generate significant value and play a global role in the provision of high quality services to enhance the discovery and development of novel, effective antibody therapeutics."

 

Enquiries:

 

Fusion Antibodies plc

www.fusionantibodies.com

Simon Douglas, Chairman

Via Walbrook PR

James Fair, CFO

 

 

Allenby Capital Limited

Tel: +44 (0)20 3328 5656 

James Reeve / Vivek Bhardwaj (Corporate Finance)

 

Tony Quirke (Sales and Corporate Broking)

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893

 

 

 

The following disclosures are made in accordance with the AIM Rules for Companies:

 

Adrian Robert Kinkaid, aged 55, is or has been a director or partner of the following companies and partnerships in the past five years:

 

Current directorships/partnerships: 

Scorpio Bioscience Ltd

 

Directorships and partnerships held within the last five years:

BioFab Ltd

MIP Diagnostics Ltd

Lumabs BV

 

Dr Kinkaid does not hold any ordinary shares in the Company

 

Save for the information set out above, there are no further disclosures to be made in accordance with Rule 17, Schedule 2(g) of the AIM Rules for Companies in respect of the appointment of Dr Kinkaid.

 

About Fusion Antibodies plc

Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

 

Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.

 

At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,

 

Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEDLFLLDLXBBD
Date   Source Headline
13th Aug 20187:00 amRNSTrading Update
20th Jun 20181:06 pmRNSOngoing discussions with MAB Discovery
24th May 20187:00 amRNSReceipt of additional grants from Invest NI
9th May 20183:40 pmRNSHolding(s) in Company
23rd Apr 201810:09 amRNSInvestor presentation
5th Mar 20187:00 amRNSTrading Statement
1st Mar 20187:00 amRNSReceipt of grants from Invest Northern Ireland
16th Jan 201810:06 amRNSDirector dealing
21st Dec 20179:35 amRNSHolding(s) in Company
21st Dec 20179:33 amRNSHolding(s) in Company
19th Dec 20177:00 amRNSHolding(s) in Company
19th Dec 20177:00 amRNSHolding(s) in Company
18th Dec 20178:00 amRNSAdmission to AIM and first day of dealings
10th Mar 20098:45 amRNSNotice of De-Listing
12th Feb 20093:37 pmRNSCompulsory Acqn of Shares
2nd Feb 20097:00 amRNSNet Asset Value(s)
29th Jan 20097:00 amRNSOffer Update
15th Jan 20097:00 amRNSOffer Update
9th Jan 20097:00 amRNSOffer Update
7th Jan 200911:55 amRNSRule 8.1- Fabian Romania Limited
24th Dec 200812:59 pmRNSOffer Document Posted
23rd Dec 20086:01 pmRNSRule 8.1- Fabian Romania Limited
22nd Dec 20084:16 pmBUSRule 8.3 - Fabian Romania Ltd.
22nd Dec 200810:46 amRNSRule 8.1- Fabian Romania Limited
19th Dec 20082:53 pmRNSCompulsory Acqn of Shares
19th Dec 20087:00 amRNSOffer for Fabian Romania Limited
5th Dec 20087:00 amRNSChange of Nominated Adviser's Name
11th Nov 20087:00 amRNSSite Update
10th Nov 200812:02 pmRNSHolding(s) in Company
7th Nov 20084:56 pmRNSHolding(s) in Company
4th Nov 200810:59 amRNSHolding(s) in Company
3rd Nov 200810:31 amRNSHolding(s) in Company
31st Oct 20086:27 pmRNSStatement re acquisition of shares
27th Oct 20087:00 amRNSQ3 Net Asset Value
29th Sep 20087:00 amRNSInterim Results
24th Sep 20087:00 amRNSNotice of Interim Results
30th Jul 20087:00 amRNSNet Asset Value(s)
24th Jul 20087:00 amRNSResult of AGM
26th Jun 20084:50 pmRNSAnnual Report and Accounts
24th Jun 20087:00 amRNSFinal Results
17th Jun 20087:00 amRNSNotice of Results
11th Jun 20087:00 amRNSAcquisition
28th Apr 20087:00 amRNSNet Asset Value(s)
13th Mar 200810:48 amRNSHolding(s) in Company
4th Feb 20087:00 amRNSNet Asset Value(s)
21st Jan 20085:50 pmRNSHolding(s) in Company
22nd Nov 20077:02 amRNSDirector/PDMR Shareholding
22nd Nov 20077:01 amRNSChange of Adviser
22nd Oct 20077:01 amRNSNet Asset Value(s)
28th Sep 200710:27 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.